New Delhi, India -- (SBWire) -- 08/13/2018 --Hepatitis Delta is the most severe form of viral hepatitis in humans and is caused by infection with the hepatitis delta virus (HDV). The defective RNA virus requires the help of hepatitis B virus (HBV) for virion assembly and penetration into hepatocytes. The help obtained by the HDV genome from HBV is limited to the sharing of envelope proteins. These proteins are needed to facilitate the assembly of the HDV genome into new virus particles, an, in turn, to allow the attachment and entry of HDV into new host cells. Hepatitis D has segmented on the basis if severity as Fulminant Hepatitis, Acute HDV & chronic HDV.
As per the estimates by DelveInsight, the total 8MM prevalent cases of Hepatitis D were found to be 10,546,938 in 2016, out of which the highest prevalent cases of this disease were seen in China, which accounted for approximately 96% of the total prevalent cases. According to DelveInsight's analysis, it has been observed that based on severity, the majority of cases were that of chronic HDV as compared to Fulminant and Acute HDV cases.
The prevalent population is expected to experience a high growth rate in coming years, mainly due to increased awareness and the growth of diseased population in the 8MM.
Click Here for the free Detailed Sample Page Hepatitis D Market Insights, Epidemiology and Market Forecast
There is no cure or vaccine for Hepatitis D and the current market is based on the use of antiviral nucleotide analogues, conventional interferon and off-label use of pegylated Interferon. Antiviral nucleotide analogues for HBV have shown the limited effect on HDV replication. Interferon alpha has demonstrated better efficacy against HCD but the response rate is low and is associated with significant side effects. There is not much progress in treatment methods for Hepatitis D after Interferons, only off-label use of pegylated Interferon has reduced the doses of conventional interferon from thrice a week to once a week. The lack of targeted approved therapy to inhibit HDV replication poses a need to gain insight into relevant molecular virology to identify potential candidate targets, consequently the development of novel therapeutic agents to resiliently control HDV replication or to cure HDV infection or HBV/HDV infection.
DelveInsight's 'Hepatitis D - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Hepatitis D in the United States, EU5 (France, Germany, Italy, Spain and United Kingdom), Japan and China.
The Report provides the current treatment practices, emerging drugs, the market share of the individual therapies, current and forecasted market size of Hepatitis D from 2016 to 2027 segmented by eight major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to find best of the opportunities and assess the underlying potential of the market.
Geography Covered:
- The United States
- EU5 (France, Germany, Italy, Spain and the United Kingdom)
- Japan
- China
Study Period: 2016-2027
Hepatitis D - Disease Understanding and Treatment Algorithm
The DelveInsight Hepatitis D market report gives the thorough understanding of Hepatitis D by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Hepatitis D in the US, Europe and Japan and China.
Hepatitis D Epidemiology
The Hepatitis D epidemiology division provide the insights about historical and current patient pool and forecasted trend for each of the 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
According to DelveInsight, total prevalent population of Hepatitis D in 8 major markets was estimated to be 10,546,938 in 2016.
Hepatitis D Drug Chapters
This segment of Hepatitis D report encloses the detailed analysis of marketed drugs and late stage (Phase-III & Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Detailed chapters for all the upcoming therapies i.e., Pegasys (Hoffmann-La Roche), Pegylated interferon lambda 1a (Eiger Biopharmaceuticals Inc.), Myrcludex B (MYR Pharma), Lonafarnib (Eiger Bio-Pharmaceuticals), REP 2139-Ca (Replicor Inc.) etc., have been covered in the report.
Hepatitis D Market Outlook
The Hepatitis D market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of off-label therapies, marketed therapies and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Hepatitis D was estimated to be USD 656 Million in 2016, and is expected to increase from 2016-2027.
Hepatitis D Drugs Uptake
This section focusses on the rate of uptake of the potential drugs that will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Hepatitis D Report Insights
- Patient Population in Hepatitis D
- Therapeutic Approaches in Hepatitis D
- Hepatitis D Pipeline Analysis
- Hepatitis D Market Size and Trends
- Hepatitis D Market Opportunities
- Impact of upcoming Therapies in Hepatitis D
Hepatitis D Report Key Strengths
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
Hepatitis D Report Assessment
- Current Treatment Practices in Hepatitis D
- Unmet Needs in Hepatitis D
- Detailed Hepatitis D Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Hepatitis D Market Scenario